Chang, Shao-Chun
AstraZeneca (United States)
2 papers on CoChat
Most cited papers
- Verified
Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer
Cited by 952
- Verified
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
O’Reilly, E. M., Oh, D.-Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., Fisher, G., Hezel, A., Chang, S.-C., Vlahovic, G., et al. (2019) · JAMA Oncology
Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers
Cited by 767
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free